Adicet Bio, Inc.
Recorded as renamed to Adicet Therapeutics, Inc. (2022)
When these terms end
Fee deadlines
No maintenance fee falls due on this company's record before Nov 21, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Showing 1 to 4 of 4
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,371,663 | Engineered γδ T-cells In force · USPTO record | In force | USPTO record | |
| US 11,001,642 | Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same In force · USPTO record | In force | USPTO record | |
| US 11,485,785 | Antibodies capable of binding HLA-A2/TyrD in an HLA restricted manner and uses thereof In force · USPTO record | In force | USPTO record | |
| US 12,252,547 | Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same In force · USPTO record | In force | USPTO record |
Sources and methods
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 1 no status recorded
Showing 1 to 3 of 3, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 17/782,129 | Methods for Expanding Gamma Delta T-Cell Populations with Multivalent Agents and Compositions Thereof | Dec 3, 2020 | Pending |
| 17/298,903 | Methods for Selective in Vivo Expansion of Gamma Delta T-Cell Populations and Compositions Thereof | Dec 3, 2019 | Pending |
| 15/579,974 | Jun 8, 2016 | No status recorded |